Product Overview
[Drug Name]
Generic Name: Idebenone Tablets
Trade Name: Jinborui
English Name: Idebenone Tablets
Chinese Pinyin: Ai Di Ben Kun Pian
[Ingredients]
The main ingredient is idebenone. Its chemical name is 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone.
[Properties]
This product is a white sugar-coated tablet with an orange-yellow core.
[Indications]
Cerebral impairment caused by chronic cerebrovascular disease and brain trauma. It can improve subjective symptoms, language impairment, anxiety, depression, memory loss, intellectual impairment, and other mental and behavioral disorders.
[Dosage and Administration]
Oral administration. Adults: 30 mg (one tablet) three times a day after meals.
[Adverse Reactions]
The incidence of adverse reactions is approximately 3%, mainly including allergic reactions, rash, nausea, loss of appetite, diarrhea, excitement, insomnia, and dizziness. Leukopenia and liver damage may occur occasionally.
[Contraindications]
1. The safety of this drug for pregnant women has not been fully established, and therefore it is contraindicated in pregnant women. 2. Because this drug can be transferred into breast milk, it should be used with caution in lactating women.
[Precautions]
With long-term use, liver function tests such as GOT and GPT should be monitored regularly.
[Use in Special Populations]
Precautions for Children:
Unknown
Precautions for Pregnancy and Lactation:
1. The safety of this drug for pregnant women has not been fully established, and therefore it is contraindicated in pregnant women. 2. Because this drug can be transferred into breast milk, it should be used with caution in lactating women.
Precautions for Elderly:
Unknown
[Drug Interactions]
Drug interactions may occur if used concurrently with other medications. Please consult your physician or pharmacist for details.
[Pharmacological Actions]
This drug is used to improve brain metabolism and psychiatric symptoms. It activates mitochondrial respiratory activity, improves brain energy metabolism in cerebral ischemia, improves brain glucose utilization, increases brain ATP production, inhibits lipid peroxide production in brain mitochondria, and inhibits membrane disorders caused by lipid peroxidation in brain mitochondria. This product has low toxicity and side effects. The LD50 is 10,000 mg/kg in mice and rats, 20 mg/kg/day orally in rats for six months, and 100 mg/kg/day orally in dogs for one year. No significant toxicity has been observed. It is not teratogenic, carcinogenic, or mutagenic.
[Storage]
Store tightly in a cool, dark place.
[Specifications]
30 mg
[Packaging]
Aluminum-plastic packaging, 12 tablets/box.
[Expiry Period]
36 months.
[Approval Number]
National Medicine Standard H10970363
[Manufacturer]
Company Name: Shenzhen Neptunus Pharmaceutical Co., Ltd.
